ESMO 2017 Highlights in Melanoma: Milestones in Adjuvant Treatment

Speaker: Olivier Michielin

Karl Lewis reports the results of a study of adjuvant vemurafenib in patients with completely resected BRAF V600+ melanoma at high risk for recurrence, addressing the very legitimate question of the activity in adjuvant setting after seeing its impact in the metastatic setting.

Olivier Michielin discusses the results of 3 major adjuvant melanoma studies presented at the ESMO 2017 Congress.

Jeffrey Weber presents the very positive results from CheckMate 238 on resected melanoma showing that treatment with nivolumab translated into a 35% reduction of relapse over time compared with ipilimumab. Nivulomab showed clinically and statistically significant benefit and was also less toxic.

Alex Hauschild says that adjuvant treatment of high risk patients with resected melanoma is still a challenge. The COMBI-AD results associating adjuvant dabrafenib and trametinib compared with placebo in resected stage III BRAF V600 mutant melanoma showed excellent results in both relapse-free and overall survival at 3 years.

Karl Lewis reports the results of a study of adjuvant vemurafenib in patients with completely resected BRAF V600+ melanoma at high risk for recurrence, addressing the very legitimate question of the activity in adjuvant setting after seeing its impact in the metastatic setting.

This very well conducted study didn’t show any long-term benefit after the one-year adjuvant treatment was stopped. Olivier Michielin explains that the design suffered from lack of evidence of the increased efficacy of dual agents when the study was started. In the future, single agents BRAF inhibitors will not be our choice for adjuvant therapy of melanoma.

Abstracts

  • LBA8_PR - Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: a randomized, double-blind, phase 3 trial (CheckMate 238)
  • LBA6_PR - COMBI-AD: A Phase III randomized double blind study of dabrafenib (D) in combination with trametinib (T) versus two placebos in the adjuvant treatment of high-risk Stage III BRAF V600 mutation positive melanoma
  • LBA7_PR - BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma at high risk for recurrence LBA5646: CheckMate 238

More resources from ESMO 2017 Congress